| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yixin Zhang, Xuan Liu, Ying Yang, Yihao Zhang, Qiang He, Feiyu Xu, Xinjuan Jin, Junqi Gao, Yuan Yao, Dexin Yu, Bernhard Hommel, Xingxing Zhu, Kangcheng Wang, Wenxin Zhan. Revealing complexity: Segmentation of hippocampal subfields in adolescents with major depressive disorder reveals specific links to cognitive dysfunctions. European psychiatry : the journal of the Association of European Psychiatrists. 2024-02-23. PMID:38389334. |
revealing complexity: segmentation of hippocampal subfields in adolescents with major depressive disorder reveals specific links to cognitive dysfunctions. |
2024-02-23 |
2024-02-25 |
Not clear |
| Xiao-Hui Li, Hong-Can Zhu, Xue-Min Cui, Wang Wang, Lin Yang, Li-Bo Wang, Neng-Wei Hu, Dong-Xiao Dua. Death-associated protein kinase 1 is associated with cognitive dysfunction in major depressive disorder. Neural regeneration research. vol 18. issue 8. 2023-02-08. PMID:36751808. |
these results indicate that dapk1 may be a potential reason and therapeutic target of cognitive dysfunction in major depressive disorder. |
2023-02-08 |
2023-08-14 |
mouse |
| Xiao-Hui Li, Hong-Can Zhu, Xue-Min Cui, Wang Wang, Lin Yang, Li-Bo Wang, Neng-Wei Hu, Dong-Xiao Dua. Death-associated protein kinase 1 is associated with cognitive dysfunction in major depressive disorder. Neural regeneration research. vol 18. issue 8. 2023-02-08. PMID:36751808. |
therefore, dapk1 may be related to cognitive dysfunction in major depressive disorder. |
2023-02-08 |
2023-08-14 |
mouse |
| Elizabeth C Gregory, Ivan J Torres, Daniel M Blumberger, Jonathan Downar, Zafiris J Daskalakis, Fidel Vila-Rodrigue. Repetitive Transcranial Magnetic Stimulation Shows Longitudinal Improvements in Memory in Patients With Treatment-Resistant Depression. Neuromodulation : journal of the International Neuromodulation Society. 2022-01-28. PMID:35088728. |
cognitive dysfunction (cd) is a commonly reported symptom of major depressive disorder (mdd). |
2022-01-28 |
2023-08-13 |
Not clear |
| Marina Sagud, Matea Nikolac Perkovic, Anja Dvojkovic, Nenad Jaksic, Bjanka Vuksan-Cusa, Maja Zivkovic, Zorana Kusevic, Alma Mihaljevic-Peles, Nela Piva. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram. Psychopharmacology. vol 238. issue 6. 2021-06-01. PMID:33560444. |
cognitive dysfunction is frequent in major depressive disorder (mdd), and brain-derived neurotrophic factor (bdnf) is involved both in regulation of cognition and in therapeutic response in mdd. |
2021-06-01 |
2023-08-13 |
Not clear |
| Joshua D Manduca, Rachel-Karson Thériault, Melissa L Perreaul. Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction? Pharmacological research. vol 157. 2021-05-31. PMID:32305493. |
elevated gsk-3 activity has been implicated in cognitive dysfunction associated with various disorders including alzheimer's disease, schizophrenia, type 2 diabetes, traumatic brain injury, major depressive disorder and bipolar disorder. |
2021-05-31 |
2023-08-13 |
Not clear |
| Wei Xin, Ran Yu, Lun Zha. Event-related-potential based evidence of cognitive dysfunction of processing emotional faces in major depressive disorder patients. Neuroscience letters. vol 742. 2021-04-29. PMID:33278508. |
event-related-potential based evidence of cognitive dysfunction of processing emotional faces in major depressive disorder patients. |
2021-04-29 |
2023-08-13 |
Not clear |
| Matthew J Knight, Natalie T Mills, Bernhard T Baun. Contemporary methods of improving cognitive dysfunction in clinical depression. Expert review of neurotherapeutics. vol 19. issue 5. 2020-08-11. PMID:31020872. |
cognitive dysfunction is prevalent in patients with major depressive disorder (mdd), with deficits observed across several domains (e.g., executive function, memory, attention). |
2020-08-11 |
2023-08-13 |
Not clear |
| Eduard Vieta, Lasse B Sluth, Christina K Olse. Corrigendum to ``The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram'' [Journal of Affective Disorders, 227 (2018) 803-809]. Journal of affective disorders. vol 236. 2019-11-20. PMID:29807616. |
corrigendum to ``the effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: a short-term, randomized, double-blind, exploratory study versus escitalopram'' [journal of affective disorders, 227 (2018) 803-809]. |
2019-11-20 |
2023-08-13 |
Not clear |
| Richard S E Keefe, George Nomikos, Wei Zhong, Michael Cronquist Christensen, William Jacobso. A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction. The international journal of neuropsychopharmacology. vol 21. issue 5. 2019-05-01. PMID:29546401. |
a subgroup analysis of the impact of vortioxetine on functional capacity, as measured by upsa, in patients with major depressive disorder and subjective cognitive dysfunction. |
2019-05-01 |
2023-08-13 |
Not clear |
| Hua Li, Aadi P Sagar, Szabolcs Kér. Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder. Journal of affective disorders. vol 241. 2019-01-29. PMID:30142589. |
microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder. |
2019-01-29 |
2023-08-13 |
Not clear |
| Eduard Vieta, Lasse B Sluth, Christina K Olse. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. Journal of affective disorders. vol 227. 2018-09-06. PMID:29673132. |
the effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: a short-term, randomized, double-blind, exploratory study versus escitalopram. |
2018-09-06 |
2023-08-13 |
Not clear |
| Sharee N Light, Linas A Bieliauskas, Jon-Kar Zubiet. "Top-Down" Mu-Opioid System Function in Humans: Mu-Opioid Receptors in Ventrolateral Prefrontal Cortex Mediate the Relationship Between Hedonic Tone and Executive Function in Major Depressive Disorder. The Journal of neuropsychiatry and clinical neurosciences. vol 29. issue 4. 2018-05-29. PMID:28412878. |
cognitive dysfunction and anhedonia, the reduced ability to experience pleasure, are commonly comorbid symptoms that are persistent following successful resolution of negative affect in major depressive disorder (mdd). |
2018-05-29 |
2023-08-13 |
Not clear |
| Jonathan P Stange, Katie L Bessette, Lisanne M Jenkins, Amy T Peters, Claudia Feldhaus, Natania A Crane, Olusola Ajilore, Rachel H Jacobs, Edward R Watkins, Scott A Langenecke. Attenuated intrinsic connectivity within cognitive control network among individuals with remitted depression: Temporal stability and association with negative cognitive styles. Human brain mapping. vol 38. issue 6. 2018-03-01. PMID:28345197. |
many individuals with major depressive disorder (mdd) experience cognitive dysfunction including impaired cognitive control and negative cognitive styles. |
2018-03-01 |
2023-08-13 |
Not clear |
| Pia Berner Hansson, Robert Murison, Anders Lund, Åsa Hamma. Cognitive functioning and cortisol profiles in first episode major depression. Scandinavian journal of psychology. vol 56. issue 4. 2016-12-13. PMID:26032571. |
major depressive disorder (mdd) is often associated with high levels of stress and disturbances in the hypothalamic pituitary adrenal (hpa) system, yielding high levels of cortisol, in addition to cognitive dysfunction. |
2016-12-13 |
2023-08-13 |
Not clear |
| Beatrice Bortolato, Kamilla W Miskowiak, Cristiano A Köhler, Michael Maes, Brisa S Fernandes, Michael Berk, André F Carvalh. Cognitive remission: a novel objective for the treatment of major depression? BMC medicine. vol 14. 2016-08-15. PMID:26801406. |
cognitive dysfunction in major depressive disorder (mdd) encompasses several domains, including but not limited to executive function, verbal memory, and attention. |
2016-08-15 |
2023-08-13 |
Not clear |
| Alan L Pehrson, Steven C Leiser, Maria Gulinello, Elena Dale, Yan Li, Jessica A Waller, Connie Sanche. Treatment of cognitive dysfunction in major depressive disorder--a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. European journal of pharmacology. vol 753. 2016-03-14. PMID:25107284. |
treatment of cognitive dysfunction in major depressive disorder--a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. |
2016-03-14 |
2023-08-13 |
Not clear |
| Atul R Mahableshwarkar, John Zajecka, William Jacobson, Yinzhong Chen, Richard S E Keef. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 40. issue 8. 2016-03-08. PMID:25687662. |
this multicenter, randomized, double-blind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of vortioxetine (10-20 mg) on cognitive function in adults (aged 18-65 years) diagnosed with major depressive disorder (mdd) who self-reported cognitive dysfunction. |
2016-03-08 |
2023-08-13 |
Not clear |
| Tracy L Greer, Bruce D Grannemann, Matthieu Chansard, Alyzae I Karim, Madhukar H Trived. Dose-dependent changes in cognitive function with exercise augmentation for major depression: results from the TREAD study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 2. 2015-11-17. PMID:25453481. |
cognitive dysfunction has been repeatedly observed in major depressive disorder (mdd), particularly in areas of attention, verbal and nonverbal learning and memory, and executive functioning. |
2015-11-17 |
2023-08-13 |
human |
| Andre F Carvalho, Kamilla K Miskowiak, Thomas N Hyphantis, Cristiano A Kohler, Gilberto S Alves, Beatrice Bortolato, Paulo Marcelo G Sales, Rodrigo Machado-Vieira, Michael Berk, Roger S McIntyr. Cognitive dysfunction in depression - pathophysiology and novel targets. CNS & neurological disorders drug targets. vol 13. issue 10. 2015-09-21. PMID:25470397. |
major depressive disorder (mdd) is associated with cognitive dysfunction encompassing several domains, including memory, executive function, processing speed and attention. |
2015-09-21 |
2023-08-13 |
Not clear |